ArticleThe Journal of pathology2019
Non-ossifying fibroma: A RAS-MAPK driven benign bone neoplasm.
Article in The Journal of pathology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 44 citations in OpenAlex.
- What's new in pediatric bone sarcomas and benign bone tumors.Journal of children's orthopaedics · 2026Article
- Unveiling a Silent Bone Lesion: Pathological Fracture in a Child With Non-Ossifying Fibroma.Clinical case reports · 2026Article
- Surgically Treated Benign Bone Tumors and Tumor-like Conditions in the Pediatric Population-A 10-Year Institutional Experience.Children (Basel, Switzerland) · 2025Article
- Non-Ossifying Fibromas: A 2025 Review.Journal of clinical medicine · 2025Review
- Pathological fractures in the paediatric orthopaedic patient population: a current concepts overview of assessment and management.European journal of orthopaedic surgery & traumatology : orthopedie traumatologie · 2025Review
- A Promising Paradigm Shift in Cancer Treatment with FGFR Inhibitors.Anti-cancer agents in medicinal chemistry · 2025Review
- Article
- Current challenges and practical aspects of molecular pathology for bone and soft tissue tumors.Virchows Archiv : an international journal of pathology · 2024Review
- Literature Review, Case Presentation and Management of Non-ossifying Fibroma of Right Angle of Mandible: More Than just a Cortical Defect!Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India · 2024Article
- An unusually aggressive multiple non-ossifying fibroma of the distal tibia and fibula: A case report.Bone reports · 2023Article
- DNA methylation profile discriminates sporadic giant cell granulomas of the jaws and cherubism from their giant cell-rich histological mimics.The journal of pathology. Clinical research · 2023Article
- Giant-cell-poor giant cell tumor of bone: report of two cases and literature review.Skeletal radiology · 2023Review
- Brown Tumour in Chronic Kidney Disease: Revisiting an Old Disease with a New Perspective.Cancers · 2023Review
- Edema-like marrow signal intensity (ELMSI) associated with nonossifying fibroma (NOF) on MRI: an uncommon finding in a common bone lesion.Skeletal radiology · 2023Article
- Oestrogen receptor expression distinguishes non-ossifying fibroma from other giant cell containing bone tumours.Virchows Archiv : an international journal of pathology · 2022Article
- Article
- Molecular findings in maxillofacial bone tumours and its diagnostic value.Virchows Archiv : an international journal of pathology · 2020Review
- Recurrent Fusion of the Genes for High-mobility Group AT-hook 2 (Cancer genomics & proteomicsArticle
- Neurofibromatosis Type 1 With Cherubism-like Phenotype, Multiple Osteolytic Bone Lesions of Lower Extremities, and Alagille-syndrome: Case Report With Literature Survey.In vivo (Athens, Greece)Article
Corrections and comments
- Comment on
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-ossifying fibroma (NOF) has been an intriguing entity since its first description. It is the most common bone tumour, is usually asymptomatic affecting children and adolescents, is composed of a heterogeneous cell population, and undergoes spontaneous regression after puberty. In a recent article in The Journal of Pathology, Baumhoer and colleagues demonstrate mutations activating the RAS-MAPK pathway (KRAS, FGFR1 and NF1) in ∼80% of the tumours. Activation of the RAS-MAPK pathway by somatic mutations is found in a plethora of tumour types, both benign and malignant, while germline mutations cause a wide range of syndromes collectively termed the RASopathies. Their findings indicate that NOF, for long thought to be reactive, should be considered a true neoplasm. Moreover, their data suggest that only a subset of cells in the lesion contain the mutation. A second cell population consisting of histiocytes and osteoclast-like giant cells appears to be reactive. This intimate relation between WT and mutant cells is also frequently encountered in other benign and locally aggressive bone tumours and seems essential for tumourigenesis. The spontaneous regression remains enigmatic and it is tempting to speculate that pubertal hormonal signalling, especially increased oestrogen levels, affect the balance between mutant and WT cells. © 2019 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.